Radient Pharmaceuticals Corporation fka RXPC

[Gold Seeker]

Status Examination is in progress
Database last updated on 06.12.2013
Most recent event Tooltip 29.10.2013 New entry: Application deemed to be withdrawn: despatch of communication + time limit
Applicant(s) For all designated states
AMDL, Inc.
2492 Walnut Avenue, Suite 100
Tustin, CA 92780-6953 / US
[2012/06]
Inventor(s) 01 / SMALL-HOWARD, Andrea
12403 Jersey Avenue
Norwalk CA 90650 / US
[2012/06]
Representative(s) Potter Clarkson LLP
The Belgrave Centre, Talbot Street, Nottingham
NG1 5GG / GB
[2013/37]
Former [2012/06] Wright, Andrew John
Potter Clarkson LLP Park View House 58 The Ropewalk
Nottingham NG1 5DD / GB
Application number, filing date 09789550.2 30.03.2009
WO2009US38833
Priority number, date deleted
[2012/06]
Filing language EN
Procedural language EN
Publication Type : A1 Application with search report
No. : WO2010114514
Date : 07.10.2010
Language : EN
[2010/40]
Type : A1 Application with search report
No. : EP2414843
Date : 08.02.2012
Language : EN
The application has been published by WIPO in one of the EPO official languages on 07.10.2010
[2012/06]
International and Supplementary
search report(s) International search report -
published on: EP 07.10.2010
Classification International : G01N33/574, G01N33/86
[2012/06]
Designated contracting states AT , BE , BG , CH , CY , CZ , DE , DK , EE , ES , FI , FR , GB , GR , HR , HU , IE , IS , IT , LI , LT , LU , LV , MC , MK , MT , NL , NO , PL , PT , RO , SE , SI , SK , TR [2012/06]
Title German : NACHWEIS VON FIBRIN- UND FIBRINOGEN-ABBAUPRODUKTEN SOWIE DAMIT VERBUNDENE VERFAHREN ZUR HERSTELLUNG UND VERWENDUNG ZUM NACHWEIS UND ZUR ÜBERWACHUNG EINER KREBSERKRANKUNG [2012/06]
English : DETECTION OF FIBRIN AND FIBRINOGEN DEGRADATION PRODUCTS AND ASSOCIATED METHODS OF PRODUCTION AND USE FOR THE DETECTION AND MONITORING OF CANCER [2012/06]
French : DÉTECTION DE PRODUITS DE DÉGRADATION DE FIBRINE ET DE FIBRINOGÈNE, ET PROCÉDÉS CONNEXES DE PRODUCTION ET D'UTILISATION POUR LA DÉTECTION ET LA SURVEILLANCE D'UN CANCER [2012/06]
Entry into regional phase 18.10.2011 National basic fee paid
18.10.2011 Designation fee(s) paid
18.10.2011 Examination fee paid
Examination procedure 18.10.2011 Examination requested [2012/06]
18.05.2012 Amendment by applicant (claims and/or description)
10.09.2013 Despatch of a communication from the examining division (Time limit: M04)
30.10.2013 Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time
Divisional application(s) The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 10.09.2013
Fees paid Renewal fee
30.09.2011 Renewal fee patent year 03
26.03.2012 Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
31.03.2013 05 M06 Not yet paid
Cited in International search [I] US2004033544
[Y] WO9855872
[I] Anonymous: "GenWay Biotech/AMDL-ELISA DR-70 (FDP) test" online Internet article 2007, pages 1-4, XP002556535 Retrieved from the Internet: URL:http://www.genwaybio.com/images/gw_tds/elisa_kits/40-008-355001.pdf>; [retrieved on 2009-11-19]
[X] LI X. ET AL.: "Serum concentration of AMDL DR-70 for the diagnosis and prognosis of carcinoma of the tongue" BR. J. ORAL & MAXILLOFAC. SURG., vol. 43, no. 6, December 2005 (2005-12), pages 513-515, XP002556536

DOI: http://dx.doi.org/10.1016/j.bjoms.2004.11.020
[X] KERBER A. ET AL.: "The new DR-70 immunoassay detects cancer of the gastrointestinal tract: a validation study" ALIMEN. PHARMACOL. & THER., vol. 20, no. 9, 1 November 2004 (2004-11-01), pages 983-987, XP002556537

DOI: http://dx.doi.org/10.1111/j.1365-2036.2004.02212.x
[X] WU D.F. ET AL.: "Sensitivity and specificity of DR-70(TM) lung cancer immunoassay" ANALYTICAL LETTERS, vol. 32, no. 7, May 1999 (1999-05), pages 1351-1362, XP009126042

DOI: http://dx.doi.org/10.1080/00032719908542902
[X] WU D. ET AL.: "Clinical performance of the AMDL DR-70 immunoassay kit for cancer detection" J. IMMUNOASSAY, vol. 19, no. 1, February 1998 (1998-02), pages 63-72, XP009126130
[X] RUCKER P. ET AL.: "Elevated fibrinogen-fibrin degradation products (FDP) in serum of colorectal cancer patients" ANALYTICAL LETTERS, vol. 37, no. 14, November 2004 (2004-11), pages 2965-2976, XP009126041

DOI: http://dx.doi.org/10.1081/AL-200035849
[Y] MCCABE R.P. ET AL.: "A diagnostic-prognostic test for bladder cancer using a monoclonal antibody-based enzyme-linked immunoassay for detection of urinary fibrin(ogen) degradation products" CANCER RES., vol. 44, no. 12 Part 1, December 1984 (1984-12), pages 5886-5893, XP009126033
[A] BICK R.L.: "The clinical significance of fibrinogen degradation products" SEMINARS IN THROMBOSIS AND HEMOSTASIS, vol. 8, no. 4, October 1982 (1982-10), pages 302-330, XP009126076